An additional listing on NASDAQ OMX Copenhagen is believed to make strong strategic sense for the Company. Copenhagen offers access to the international investor community and is a recognized market for healthcare companies. Listing and compliance requirements are similar in Denmark and Iceland and both exchanges are part of the NASDAQ OMX Nordic group.
Jon Sigurdsson, President & CEO: "The listing of our shares in Iceland has served us well and we remain committed to all current and future shareholders. Since our initial listing, our sales have grown more than twenty times and we have transformed into a global company. The additional listing in Copenhagen is a logical next step for us. It is aimed at facilitating trade and fair pricing of our shares and strengthening the Company's foundation for future growth."
The new listing is expected to be approved next week. Nordea Bank will be the issuing agent in Denmark. Further information will be disclosed when the application for listing has been approved.
Following the listing the Board of Directors will, in order to facilitate liquidity, consider a modest issue of new shares corresponding to 5-7% of the Company's share capital. Such an issue would be directed towards institutional investors and in this connection Ossur has engaged Nordea Markets as financial advisor.
Trading with Icelandic financial instruments is currently subject to Icelandic Foreign Exchange Rules. Investors domiciled outside Iceland will, in general, be able to trade Ossur shares freely on the Danish market. Investors domiciled in Iceland can trade Ossur shares freely on the Icelandic market.
Further information on Ossur, including an introduction brochure and additional information on the trading of Ossur shares and transfer between Iceland and Denmark can be found on Ossur's website: www.ossur.com/investors
Ossur contacts: Jon Sigurdsson, President & CEO, tel. 354 515 1300 Hjorleifur Palsson, CFO, tel. 354 515 1300 Sigurborg Arnarsdottir, IR Manager, tel. 354 664-1044
About Ossur Ossur (OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of bracing and supports, prosthetic limbs and compression therapies. A recognized "Technology Pioneer", Ossur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Ossur's educational programs and business solutions. Headquartered in Iceland, Ossur has major operations in North America and Europe, with additional distributors worldwide.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.